MARKETS / APTOF
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Aptose Biosciences Inc. APTOF
9 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 9-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -25.5
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2023 · ROE -294.0%
The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Operating income $B | · | · | · | · | · | · | · | · | · |
| EBITDA $B | · | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −10.41 | −36.38 | −227.43 | −6.80 | −0.73 | −0.67 | −0.52 | −0.86 | −0.52 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | −294.0 | −74.7 | −67.7 | −51.9 | −48.7 | −237.8 | −114.1 |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.01 | 0.09 | 0.09 | 0.08 | 0.04 | 0.03 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 36 reconciliationsAUDITED
Reconciled in 9 of 19 fiscal years. 40 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onnot stated in the filings
Incorporated inoutside the United States — SEC code A6
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017